NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Bharat Biotech allowed COVAXIN trials on children aged 12+
    Bharat Biotech allowed COVAXIN trials on children aged 12+
    1/6
    India 2 min read

    Bharat Biotech allowed COVAXIN trials on children aged 12+

    By Siddhant Pandey
    Jan 04, 2021
    06:56 pm
    Bharat Biotech allowed COVAXIN trials on children aged 12+

    Hyderabad-based pharmaceutical company Bharat Biotech has been allowed to conduct clinical trials for its COVID-19 vaccine on children above the age of 12. On Sunday, the firm's vaccine, called COVAXIN, had been granted emergency approval for use, albeit in "clinical trial mode" only. The vaccine has been undergoing Phase III trials and its efficacy is yet to be ascertained. Here are more details.

    2/6

    Yesterday, government had approved two vaccines

    On Sunday, the government had approved two vaccines: COVAXIN and Covishield (developed by AstraZeneca and Oxford University, and manufactured by Pune-based Serum Institute of India). So far, the government has said the vaccination drive will only focus on adults. However, COVAXIN has been approved in "clinical trial mode," i.e., its recipients would be tracked and monitored as if they were in a clinical trial.

    3/6

    COVAXIN already administered to children in last round of trials

    Notably, COVAXIN has already been given to children above the age of 12 in the last round of trials. It has been found "safe" so far. Phase I and II trials also showed that the vaccine had a "robust immune response."

    4/6

    Questions raised over vaccine's efficacy with trial still underway

    The approval for restricted use for COVAXIN has invited controversy as the company is yet to complete clinical trials and submit data on efficacy. The Opposition has demanded that the vaccine's use should be avoided until the trials have concluded. Meanwhile, Health Minister Dr. Harsh Vardhan has said that the Opposition was politicizing a "critical issue," adding that "science-backed protocols" were followed for approval.

    5/6

    COVAXIN more effective against mutated virus: ICMR chief

    COVAXIN is an inactivated vaccine, i.e., it uses an inactivated or killed pathogen (SARS-CoV-2) to trigger an immune response. Indian Council of Medical Research (ICMR) Director-General Dr. Balram Bhargava told The Print that the vaccine is more likely to act against the new mutant strain of the coronavirus as it uses the whole virus. The ICMR has jointly developed COVAXIN with Bharat Biotech.

    6/6

    'mRNA vaccines may not work as well against mutated virus'

    Dr. Bhargava said, "If there are say 1,000 points in a vaccine, of which two have mutated, this is still going to have 998 points to generate a response, unlike others such as mRNA vaccines, which...may not work as well when those areas mutate."

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Oxford University
    Coronavirus
    Serum Institute of India
    Bharat Biotech
    COVAXIN

    Oxford University

    'Finally paid off,' says Adar Poonawalla after Covishield gets approval India
    UK's approval to Oxford-AstraZeneca vaccine paves way for India India
    After Pfizer, Oxford-AstraZeneca's COVID-19 vaccine approved in UK Coronavirus
    Oxford/AstraZeneca vaccine should be effective against new variant: Report Coronavirus

    Coronavirus

    Politics heats up over coronavirus vaccine, BJP leaders slam detractors Akhilesh Yadav
    Private hospitals may get coronavirus vaccine by March: Serum CEO Serum Institute of India
    Honda develops a 'mask' for cars, may kill COVID-19 virus Japan
    Coronavirus: India's tally reaches 10.34 million with 16K+ new cases India

    Serum Institute of India

    All you need to know about vaccines approved in India Drugs Controller General of India
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI Drugs Controller General of India
    India could approve coronavirus vaccine soon, key meeting today Pfizer
    Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution Narendra Modi

    Bharat Biotech

    Coronavirus vaccine: Bharat Biotech's COVAXIN gets expert panel nod Union Health Ministry
    Coronavirus vaccination may start in January, says Health Minister NITI Aayog
    COVID-19 vaccine: India to produce 300 million Sputnik V doses India
    India's neighbors train experts for clinical trials of COVID-19 vaccine Sri Lanka

    COVAXIN

    No emergency approval for SII, Bharat Biotech's vaccine candidates yet Serum Institute of India
    Now, Bharat Biotech seeks emergency use approval for COVAXIN Indian Council of Medical Research (ICMR)
    Haryana minister, who received dose of coronavirus vaccine, tests positive India
    Bharat Biotech vaccine trials continued despite 'adverse event' in August Indian Council of Medical Research (ICMR)
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023